Serum adipocyte fatty acid binding proteins and adiponectin in patients with coronary artery disease: The significance of A-FABP/adiponectin ratio

Clinica Chimica Acta

Volumn 411, Issue 21-22, 2010, Pages 1761-1765

  Jin, Jing ^a,b   Peng, Dao quan ^a   Yuan, Shu guang ^a   Zhao, Shui ping ^a   Ning, Xiao hui ^a   Wang, Shu hui ^a   Li, Song lin ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b First Hospital of Changsha   (China)

Author keywords

Adiponectin; Coronary artery disease; Fatty acid binding protein

Indexed keywords

ADIPONECTIN; FATTY ACID BINDING PROTEIN 4;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEALTH CARE QUALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CODING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SEX DIFFERENCE;

ADIPOCYTES; ADIPONECTIN; AGED; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEX FACTORS;

EID: 77956494367     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.07.031     Document Type: Article

References (28)

1. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
2. Lau D.C., Dhillon B., Yan H., Szmitko P.E., Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol 2005, 288:H2031-H2041.
3. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin in obesity. Biochem Biophys Res Commun 1999, 257:79-83.
4. Matsuzawa Y., Funahashi T., Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 1999, 892:146-154.
5. Kadowaki T., Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev 2005, 26:439-451.
6. Weyer C., Funahashi T., Tanaka S., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
7. Makowski L., Boord J.B., Maeda K., et al. Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med 2001, 7:699-705.
8. Boord J.B., Maeda K., Makowski L., et al. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002, 22:1686-1691.
9. Furuhashi M., Tuncman G., Görgün C.Z., et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007, 447:959-965.
10. Judkins M.P. Percutaneous transfemoral selective coronary arteriography. Radiol Clin North Am 1968, 6:467-492.
11. Gensini G.G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol 1983, 51:606.
12. Rhee E.J., Lee W.Y., Park C.Y., et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol 2009, 160:165-172.
13. Xu A., Wang Y., Xu J.Y., et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006, 52:405-413.
14. Xu A., Tso A.W., Cheung B.M., et al. Circulating adipocyte-fatty acid binding protein concentrations predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007, 115:1537-1543.
15. Yeung D.C., Xu A., Cheung C.W., et al. Serum adipocyte fatty acid-binding protein concentrations were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:1796-1802.
16. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet 2005, 365:1415-1428.
17. Xu A., Chan K.W., Hoo R.L., et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005, 280:18073-18080.
18. Yokota T., Oritani K., Takahashi I., et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000, 96:1723-1732.
19. Ajuwon K.M., Spurlock M.E. Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1220-R1225.
20. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S.L., Cooper G.J.S. The fat derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver disease in mice. J Clin Invest 2003, 112:91-100.
21. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103:1057-1063.
22. Yamauchi T., Kamon J., Waki H., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
23. Fu Y., Luo N., Lopes-Virella M.F. GarveyWT. The adipocyte lipid binding protein (ALBP/aP2) gene facilitates foam cell formation in human THP-1 macrophages. Atherosclerosis 2002, 165:259-269.
24. Makowski L., Brittingham K.C., Reynolds J.M., Suttles J., Hotamisligil G.S. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. J Biol Chem 2005, 280:12888-12895.
25. Scheja L., Makowski L., Uysal K.T., et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999, 48:1987-1994.
26. Coe N.R., Simpson M.A., Bernlohr D.A. Targeted disruption of the adipocytes lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid concentrations. J Lipid Res 1999, 40:967-972.
27. Hotamisligil G.S., Johnson R.S., Distel R.J., Ellis R., Papaioannou V.E., Spiegelman B.M. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996, 274:1377-1379.
28. Uysal K.T., Scheja L., Wiesbrock S.M., Bonner-Weir S., Hotamisligil G.S. Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology 2000, 141:3388-3396.